Role of Host Filamin Proteins in Regulating Filovirus Entry and Egress
Role of Host Filamin Proteins in Regulating Filovirus Entry and Egress
批准号:
10644499
负责人:
RONALD N HARTY
金额:
$26.83万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-03-10 至 2025-02-28
关键词:
ActinsAffectAntibody TherapyAntiviral TherapyBAG3 geneBiochemicalBiological AssayCell FractionationCell SeparationCell divisionCell membraneCell physiologyCellsCellular MorphologyCessation of lifeComplexCytokinesisDevelopmentDisease OutbreaksEbolaEbola virusEyeFamilyFilopodiaFilovirusFutureGoalsHIV-1Host Defense MechanismHumanImmunologicsInfectionIntegrinsLaboratoriesLife Cycle StagesLinkLiquid substanceMagnetismMammalian CellMarburgvirusMediatingMembraneMicroscopyMolecularPathway interactionsProcessProteinsProteomeReagentRecombinantsRegulationRibonucleasesRoleSeminal fluidSiteSmall Interfering RNATestingTherapeutic InterventionTotal Internal Reflection FluorescentVesicleVesicular stomatitis Indiana virusViralViral Hemorrhagic FeversVirionVirusVirus AssemblyVirus DiseasesVirus ReplicationZoonosescell motilitychronic infectioncombatconfocal imagingcrosslinkdriving forceemerging pathogenextracellularfilamininsightlink proteinlong-term sequelaemembernonhuman primatenovelparticleprotein crosslinktraffickingubiquitin-protein ligasevirus host interaction
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Filoviruses (Ebola [EBOV] and Marburg [MARV]) are zoonotic, emerging pathogens that cause sporadic and
global outbreaks of severe hemorrhagic fever in humans and non-human primates. As EBOV and MARV can
establish persistent infections in the CNS, semen, eye, and other immunologically privileged sites inaccessible
to antibody therapy, and their re-emergence can result in long-term sequelae and death, understanding of host
defense mechanisms that could lead to the development of new antiviral therapies is more critical than ever. Our
lab is at the forefront of identifying host proteins that interact both physically and functionally with the filovirus
VP40 matrix protein, the driving force for virus assembly and egress, to regulate these late stages of virus
replication. To better understand the functional filovirus-host interactome, our laboratory has focused on direct
interactions between the PPxY Late (L) domain motif conserved in the VP40 proteins of EBOV (eVP40) and
MARV (mVP40) and modular WW-domains from select host proteins. In addition to positive regulators of filovirus
egress, we have recently identified WW-domain interactors that negatively regulate VP40-mediated budding,
including YAP/TAZ, BAG3, and WWOX. While the impact of these negative regulators is likely multifactorial and
complex, we have made the intriguing observation that filamin B, a common downstream effector of YAP/TAZ
and BAG3, acts as a potential dual regulator of live EBOV/MARV infectivity/entry and live EBOV/MARV egress.
As dual role regulation of key stages at opposite ends of the filovirus lifecycle is novel and unexpected, the
ultimate goal of this proposal is to determine how host protein filamin B mechanistically impacts the filovirus
lifecycle. Filamins are a family of actin crosslinking/stabilizing proteins that regulate actin dynamics at the plasma
membrane to control cell migration and morphology, vesicle trafficking, macropinocytosis, and cell division.
Notably, macropinocytosis
macropinosomes
is
(MPs) that are densely coated with actin, filamin, and filamin-associated proteins
a key entry pathway for filoviruses, as these viruses enter the cell in vesicles
termed
. In addition,
filamins are linked to cellular processes that mimic virion formation and/or egress such as filopodia formation,
cell migration, and cytokinesis. Thus, we hypothesize that filamin B regulates infectivity/entry of filoviruses
through effects on macropinocytosis, and regulates filovirus budding through effects on egress of filopodia-like
filovirus particles. In this exploratory proposal, we propose to investigate the mechanisms by which filamin
regulates filovirus infectivity/entry (Aim 1) and egress (Aim 2). Results from these studies will impact the field by
identifying a novel host protein(s) whose expression modulates two critical and opposite steps in the filovirus
lifecycle; entry and exit, as well as providing a better fundamental understanding of the functional filovirus-host
interactome and host defense mechanisms that could lead to the development of new antiviral therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
-
批准号:10688262
-
项目类别:
-
资助金额:$29.24万
-
财政年份:2022
-
负责人:RONALD N HARTY
-
依托单位:
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
-
批准号:10545109
-
项目类别:
-
资助金额:$30.65万
-
财政年份:2022
-
负责人:RONALD N HARTY
-
依托单位:
Role of Host Angiomotin as a Central Regulator of Filovirus Egress and Dissemination
-
批准号:10380684
-
项目类别:
-
资助金额:$22.53万
-
财政年份:2021
-
负责人:RONALD N HARTY
-
依托单位:
Role of Host Angiomotin as a Central Regulator of Filovirus Egress and Dissemination
-
批准号:10217843
-
项目类别:
-
资助金额:$28.58万
-
财政年份:2021
-
负责人:RONALD N HARTY
-
依托单位:
Modular Domains of Host Proteins Regulate Filovirus Maturation
-
批准号:9517218
-
项目类别:
-
资助金额:$24.64万
-
财政年份:2018
-
负责人:RONALD N HARTY
-
依托单位:
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
-
批准号:10257889
-
项目类别:
-
资助金额:$101.7万
-
财政年份:2018
-
负责人:RONALD N HARTY
-
依托单位:
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
-
批准号:10368115
-
项目类别:
-
资助金额:$101.54万
-
财政年份:2018
-
负责人:RONALD N HARTY
-
依托单位:
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
-
批准号:10599837
-
项目类别:
-
资助金额:$101.29万
-
财政年份:2018
-
负责人:RONALD N HARTY
-
依托单位:
DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS AGAINST RNA VIRUSES
-
批准号:8903846
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2015
-
负责人:RONALD N HARTY
-
依托单位:
Innate Immune Regulation of Intracellular Pathways Involved in Filovirus Budding
-
批准号:8635498
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2013
-
负责人:RONALD N HARTY
-
依托单位:
Host-Oriented Therapeutics Targeting Filovirus Budding.
-
批准号:8853616
-
项目类别:
-
资助金额:$46.66万
-
财政年份:2012
-
负责人:RONALD N HARTY
-
依托单位:
Host-Oriented Therapeutics Targeting Filovirus Budding.
-
批准号:8490299
-
项目类别:
-
资助金额:$22.27万
-
财政年份:2012
-
负责人:RONALD N HARTY
-
依托单位:
Host-Oriented Therapeutics Targeting Filovirus Budding.
-
批准号:8389432
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:RONALD N HARTY
-
依托单位:
Host-Oriented Therapeutics Targeting Filovirus Budding.
-
批准号:9088302
-
项目类别:
-
资助金额:$47.28万
-
财政年份:2012
-
负责人:RONALD N HARTY
-
依托单位:
Innate Immune Defenses Against Filoviruses.
-
批准号:8076883
-
项目类别:
-
资助金额:$23.76万
-
财政年份:2010
-
负责人:RONALD N HARTY
-
依托单位:
Innate Immune Defenses Against Filoviruses.
-
批准号:7964676
-
项目类别:
-
资助金额:$19.99万
-
财政年份:2010
-
负责人:RONALD N HARTY
-
依托单位:
Role of ISG15 in Inhibition of Ebola Virus Budding
-
批准号:7927824
-
项目类别:
-
资助金额:$18.51万
-
财政年份:2007
-
负责人:RONALD N HARTY
-
依托单位:
Packaging of Ebola Virus RNA into Budding VLPs
-
批准号:7339650
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2007
-
负责人:RONALD N HARTY
-
依托单位:
Role of ISG15 in Inhibition of Ebola Virus Budding
-
批准号:7391373
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2007
-
负责人:RONALD N HARTY
-
依托单位:
Packaging of Ebola Virus RNA into Budding VLPs
-
批准号:7176652
-
项目类别:
-
资助金额:$23.59万
-
财政年份:2007
-
负责人:RONALD N HARTY
-
依托单位:
海外基金